Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377320 | 0.81 | RXFP1 (0.36) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL21956885 | 0.78 | RXFP1 (0.35) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL13377365 | 0.78 | RXFP1 (0.40) | RXFP1LMNATSHRNPSR1GRIA2 | |
| SCHEMBL22016172 | 0.76 | RXFP1 (0.33) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL28591800 | 0.75 | MAPT (0.38) | POLBRXFP1LMNATSHRNPSR1 | |
| SCHEMBL22899768 | 0.69 | — | — | |
| SCHEMBL13377306 | 0.65 | RXFP1 (0.33) | RXFP1LMNATSHRNPSR1 | |
| SCHEMBL21957120 | 0.65 | AR (0.41) | RXFP1 | |
| SCHEMBL22016170 | 0.64 | KIF11 (0.42) | RXFP1LMNANPSR1 | |
| SCHEMBL13377464 | 0.61 | RXFP1 (0.36) | RXFP1LMNATSHRNPSR1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | POLB 3764/4885RXFP1 2998/4885LMNA 2479/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | POLB 3894/4885RXFP1 3116/4885LMNA 3437/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | POLB 3764/4885RXFP1 2998/4885LMNA 2479/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | POLB 3764/4885RXFP1 2998/4885LMNA 2479/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | POLB 3764/4885RXFP1 2998/4885LMNA 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.